VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
Keeping up the PACE at the Scottish Medicines Consortium (SMC)There are many ways that patient centricity could be delivered when doing a health technology assessment (HTA). The Share XKeeping up the PACE at the Scottish Medicines Consortium (SMC)https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/
The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
Access to new medicines in Scotland: a perennial issueAccess to new medicines in Scotland – just as it would seem is the case everywhere – is Share XAccess to new medicines in Scotland: a perennial issuehttps://pharmaphorum.com/views-and-analysis/access-to-new-medicines-in-scotland-a-perennial-issue/
Mandatory or voluntary? A sticking point for European HTAThe long road to unified European Health Technology Assessment (HTA) is continuing. It has become clear that the Share XMandatory or voluntary? A sticking point for European HTAhttps://pharmaphorum.com/views-analysis-market-access/mandatory-or-voluntary-a-sticking-point-for-european-hta/
Late to the party but we brought friends: BeneLuxA’s horizon scanning initiativeIt can feel good to know what is coming your way; that’s no different for new medicines and Share XLate to the party but we brought friends: BeneLuxA’s horizon scanning initiativehttps://pharmaphorum.com/views-analysis-market-access/joint-horizon-scanning/
A payer’s perspective on value-based contracting (VBC)What payer wouldn’t want to ensure that they pay for value when buying drugs? If the emerging trend Share XA payer’s perspective on value-based contracting (VBC)https://pharmaphorum.com/views-analysis-market-access/payers-perspective-value-based-contracting-vbc/
Paying for value: US state of playDrug pricing in the US is a perennial topic, which is no surprise given the the US spends Share XPaying for value: US state of playhttps://pharmaphorum.com/views-analysis-market-access/us-value-based-payment-models/
Division on European HTAThere have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment Share XDivision on European HTAhttps://pharmaphorum.com/views-and-analysis/hta-european-health-technology-assessment-division-progress/
